This report describes the long-term follow-up of 56 patients with refractory partial epilepsy who, within 3 months of vigabatrin add-on therapy (3 g/day), showed a reduction in monthly seizure frequency of more than 50%. The short-term (6 months) and long-term (5 years) effects of vigabatrin on seizure frequency in this patient cohort have been published separately. The reduction in seizure frequency appeared to be long-lasting in the patients followed-up (n = 36) and, importantly, a significant number of the patients (n = 7) became seizure-free, especially during long-term treatment. Thus, the efficacy of vigabatrin appears to be progressive, at least in patients who show an early response to treatment. These results are consistent with experimental findings that suggest that vigabatrin may have anti-epileptogenic and neuroprotective effects.
Introduction
Vigabatrin is effective as an add-on therapy in approximately 50% of patients with refractory partial epilepsy, and a prolonged therapeutic response has been observed in the majority of responders [1] [2] [3] . When used as monotherapy, vigabatrin has proved to be as successful as carbamazepine 4 . However, failure of carbamazepine monotherapy is usually due to the occurrence of side-effects; whereas for vigabatrin, treatment failure is more often due to a lack of efficacy. Vigabatrin monotherapy has been shown to be well tolerated, particularly in its lack of effects on cognitive function 4 .
In preclinical research, vigabatrin has been found to inhibit the development of kindling, suggesting a potential anti-epileptogenic effect of this drug 5 . Furthermore, vigabatrin has been shown to protect neurons and neuronal function during prolonged, experimentallyinduced seizures 6 .
To study the clinical relevance of these experimental findings, the long-term outcome of epilepsy was analysed in patients who originally responded to vigabatrin add-on therapy. A retrospective approach was adopted because of the difficulties inherent in comparative group studies over periods as long as 10 years. The hypothesis was that if vigabatrin prevents cellular damage during epileptic seizures and slows epileptogenesis, then vigabatrin-treated patients should improve, or have a better prognosis than refractory patients treated by conventional antiepilepsy drugs (AEDs).
Materials and Methods
This retrospective study was performed on a cohort of patients selected from two studies of add-on vigabatrin therapy which were started approximately 11 years ago at the University Hospital of Kuopio, Finland. The original population of this study comprised 56 drugrefractory epilepsy patients (including 12 patients with a severe mental handicap). These patients had shown a response to treatment with vigabatrin 3 g/day (defined as a greater than 50% reduction in monthly seizure frequency within 3 months) and had received long-term treatment with the drug. The short-term and long-term efficacy of the treatments, and a detailed description of the patient populations, have been published elsewhere 3, 7, 8 .
Patients included in the analysis received vigabatrin treatment throughout the follow-up period. They also received their primary epilepsy management at the study clinic and had medical records available for data abstraction. Patients who discontinued the study or failed to respond (as defined above) were excluded, as were patients referred to other clinics, patients who received epilepsy surgery during the long-term treatment period and patients who did not have continuous epilepsy management at the study clinic. Clinical assessments included dose of vigabatrin, concomitant AEDs, number of seizures per month, occurrence of adverse events, and concurrent disease states.
A summary and descriptive statistical analyses were then completed, comparing baseline information with that obtained after 6 and 10 years of continuous vigabatrin treatment. SPSS/PC+ was used to perform the statistical analyses.
Results
Thirty-six of the 56 patients with uncontrolled epilepsy who showed a response within 3 months of vigabatrin add-on therapy continued to receive treatment for 6 years and had readily available medical records. Twenty-four patients were still receiving vigabatrin after 10 years. However, four of these patients underwent surgery after the first long-term treatment evaluation point (at 6 years) and were therefore excluded from the 10-year evaluation.
The median dose of vigabatrin received by patients was 3 g/day (range 1.5-5 g/day). A decrease in the number of concurrent AEDs was noted in patients followed for 6 years. Before initiating vigabatrin therapy 9, 19, and 8 patients were receiving one, two, or three AEDs respectively. At the 6-year follow-up evaluation 11, 21, and 4 patients were receiving one, two, or three AEDs respectively. The corresponding values for the patients followed-up for 10 years are illustrated in Fig. 1 . There were no major changes in concurrent AEDs between the 6-and 10-year evaluation points.
The mean monthly seizure frequency was significantly higher at baseline than after 6 years (P < 0.001, paired t-test) or 10 years (P < 0.01) of treatment. The patients who were evaluated after 6 years of vigabatrin therapy had a mean of 14.3 seizures per month at baseline. This value decreased to 5.0 after 3 months of vigabatrin treatment and to 4.9 after 6 years. The patients evaluated during the 10-year treatment period had a mean of 14.7 seizures per month during the baseline period. With vigabatrin treatment, the seizure frequency fell progressively to 5.0 seizures after 3 months, to 2.6 after 6 years and to 3.7 after 10 years (Fig. 2) . Six patients became seizure-free during the 6-year long-term treatment period. Between the 6-and 10-year followup points, an additional patient became seizure-free and three had a marked reduction in seizures, with freedom from seizures in some months. One patient, who was seizure-free at 6 years, experienced a subsequent deterioration in seizure control. Seven of the 36 patients reported side-effects at the 6-year visit compared with four patients at baseline. Two of the 20 patients evaluated at baseline and at 10 years reported side-effects. Two patients were diagnosed with lupus erythematosus disseminatus during the follow-up period of 6 years. One mentally retarded patient became psychotic and improved after the reduction of vigabatrin dose and the introduction of neuroleptics. An additional patient had reversible behavioural problems. Two mentally retarded patients were reported to improve behaviourally compared with baseline. One patient was diagnosed with arterial hypertension and appropriate medication was introduced.
Discussion
In this study, administration of vigabatrin as an add-on therapy significantly reduced the mean monthly seizure frequency during long-term follow-up of the patient cohort. Although the mean seizure frequency decreased during the first 3 months of treatment, the number of patients who were completely free of seizures increased from one after 3 months to seven after 10 years. This proportion is much higher than could be expected in the population of patients shown to be refractory to conventional epilepsy treatments.
The findings of this study are consistent with those of Tartara et al 9 . They followed-up four patients whose dose of vigabatrin, or concomitant medication did not change over 78 months. These previously refractory patients, who had been having 5-10 seizures per month for several years before vigabatrin treatment, showed a progressive decline in seizure frequency. Two patients became seizure-free after 8 and 12 months respectively, and the other two patients showed a decline in seizure frequency throughout the study period, with freedom from seizures in some months. These results tend to support the findings of this study, and suggest a mechanism whereby vigabatrin depresses the tendency for one seizure to trigger further seizures.
The conclusions drawn from uncontrolled studies of add-on therapy have certain limitations 10 . Nonetheless, the number of previously refractory patients who become totally seizure-free during long-term follow-up is a reliable end-point. All the patients in this study had suffered from epilepsy for more than 5 years and most had had epilepsy for more than 10 years. This means that they had only a minimal chance of achieving seizure-free status with their conventional medications 11 . Alternatively, the reduction in seizure frequency may simply be a function of the natural history of the disease, though this seems unlikely and has not been described before. A further explanation is that fewer seizures with any drug will mean fewer seizures in the future. Again, this has not been described with other drugs and therefore may also be excluded.
The fact that vigabatrin may affect peripheral vision had not been reported when this study was being carried out 12 . The visual fields of those patients still receiving vigabatrin are currently being evaluated. The final report concerning the visual fields of vigabatrin-treated patients at our centre is in preparation.
The results of this study suggest that the efficacy of vigabatrin increases progressively, at least in patients who show an early response to vigabatrin treatment. In addition, other studies have shown that vigabatrin does not impair cognitive function 4 . These results may be related to the experimental findings that vigabatrin is anti-epileptogenic 5 and neuroprotective 6 . However, the potential risk of visual field constriction should prompt the physician to evaluate the benefits and risks of vigabatrin for each patient and follow them up adequately with regular visual field examinations, even if they are asymptomatic.
